(Q37800182)

23 August 2017

title

Bisphosphonate-related osteonecrosis of the jaw: an overview (English)

1 reference

23 August 2017

Bisphosphonate‐related osteonecrosis of the jaw: an overview (English)

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

2 August 2024

author name string

Salvatore L. Ruggiero

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946580

2 August 2024

language of work or name

English

0 references

publication date

28 September 2010

1 reference

full work available at URL

23 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1749-6632.2010.05768.x

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

https://nyaspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1749-6632.2010.05768.x

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

Annals of the New York Academy of Sciences

2 August 2024

published in

1 reference

23 August 2017

volume

1218

1 reference

23 August 2017

page(s)

38-46

1 reference

The clinical course of bone metastases from breast cancer

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Treatment of Paget's disease--taming the wild osteoclast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

SECONDARY MALIGNANT DISEASE OF BONE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Bone and cancer: pathophysiology and treatment of metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Bone remodeling in post-menopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Bisphosphonates in the treatment of skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Bisphosphonates for treatment and prevention of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Osteonecrosis of the jaw--do bisphosphonates pose a risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Intravenous bisphosphonates and osteonecrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Osteonecrosis of the jaw in a patient on Denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Inhibition of oral mucosal cell wound healing by bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Osteonecrosis of the jaw and bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05768.X

Bone resorption and turnover in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

A new insight into the formation of osteolytic lesions in multiple myeloma

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

Palliative pamidronate treatment in patients with bone metastases from breast cancer

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

Assessment of bone quality, quantity, and turnover with multiple methodologies at multiple skeletal sites

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

Long-term safety of bisphosphonates

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1749-6632.2010.05768.X

2 August 2024

Identifiers

1 reference

23 August 2017

1 reference